Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Fátima Cardoso, Elżbieta Senkus, A. Costa et al. · Annals of Oncology · 2018 · 1.2K citations · Full text

Medicine, Oncology, Breast Oncology +16

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Medicine, Oncology, Pharmacology +14

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 841 citations · Full text

Medicine, Oncology, Pharmacology +14

United States Valuation of EQ-5D-5L Health States Using an International Protocol

A. Simon Pickard, Ernest H. Law, Ruixuan Jiang et al. · Value in Health · 2019 · 391 citations · Full text

Pharmacy, Educational Measurement, Health Assessment +16

Health state utilities for metastatic breast cancer

Andrew Lloyd, Beenish Nafees, J Narewska et al. · British Journal of Cancer · 2006 · 362 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17